These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 34116674)

  • 1. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling.
    Zhan G; Wang X; Wang X; Li J; Tang Y; Bi H; Yang X; Xia Y
    Eur J Pharmacol; 2024 Sep; 978():176712. PubMed ID: 38906237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
    Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
    Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
    Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
    J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling.
    Shentu Y; Li Y; Xie S; Jiang H; Sun S; Lin R; Chen C; Bai Y; Zhang Y; Zheng C; Zhou Y
    Int Immunopharmacol; 2021 Apr; 93():107374. PubMed ID: 33517222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.
    Shih JY; Lin YW; Fisch S; Cheng JT; Kang NW; Hong CS; Chen ZC; Chang WT
    Diabetes; 2021 Jan; 70(1):262-267. PubMed ID: 33115828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway.
    Zhang Y; Shao L; Ma A; Guan G; Wang J; Wang Y; Tian G
    Hypertens Res; 2014 Jan; 37(1):43-9. PubMed ID: 24089264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.
    Lin YW; Chen CY; Shih JY; Cheng BC; Chang CP; Lin MT; Ho CH; Chen ZC; Fisch S; Chang WT
    J Am Heart Assoc; 2021 Apr; 10(7):e019274. PubMed ID: 33749310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of PAR-1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin-Overexpressing Hypertensive Mice.
    Yokono Y; Hanada K; Narita M; Tatara Y; Kawamura Y; Miura N; Kitayama K; Nakata M; Nozaka M; Kato T; Kudo N; Tsushima M; Toyama Y; Itoh K; Tomita H
    J Am Heart Assoc; 2020 Jun; 9(12):e015616. PubMed ID: 32495720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway.
    Ding J; Tang Q; Luo B; Zhang L; Lin L; Han L; Hao M; Li M; Yu L; Li M
    Eur J Pharmacol; 2019 Sep; 859():172549. PubMed ID: 31325434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats.
    Daud E; Ertracht O; Bandel N; Moady G; Shehadeh M; Reuveni T; Atar S
    Cardiovasc Diabetol; 2021 Jul; 20(1):132. PubMed ID: 34215277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
    Luo J; Chen X; Luo C; Lu G; Peng L; Gao X; Zuo Z
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 28039944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.